(thirdQuint)Clinical Observation of S1 Capsule for Stage -A Non-small Cell Lung Cancer After Complete Resection.

 Lung cancer is the leading cause of cancer death worldwide.

 Only about 15.

6% of all lung cancer patients are alive 5years or more after diagnosis.

 Non-small Cell Lung Cancer (NSCLC) accounts for more than 85% of all lung cancer cases.

 For individuals with stage II-IIIA NSCLC after complete resection, platinum-based chemotherapy is the mainstay of first line treatment.

 Various treatment regimens have been developed to improve survival.

 S-1 capsule is an novel oral anticancer drug that combines tegafur, a prodrug of 5-fluorouracil, with gimeracil and oteracil potassium.

 S-1 capsule was considered to be an active single agent against NSCLC.

.

 Clinical Observation of S1 Capsule for Stage -A Non-small Cell Lung Cancer After Complete Resection@highlight

The purpose of this study is to evaluate S1 capsule plus Cisplatin as adjuvant treatment in stageII and IIIa non-small cell lung cancer.

 It is the first study in the world to investigate the safety and efficacy of S1 capsule using in stageII and IIIa non-small cell lung cancer patients after the complete resection.

